I was recently in a similar situation, not concerning glioblastoma but a different type of solid tumor. I'd look into either neoantigen vaccine trials from reputable universities/companies (e.g. BioNTech) or T cell therapies (e.g. Immunocore). Adding some checkpoint inhibitor as a coadjuvant might help too.
I work in the field and IMHO neoantigen vaccines are the way to go, but personalization of antigen payload is still lacking. This is a bit paradoxical as production is not that expensive, you can get a custom made one for < $6000. The trouble is to pick the right epitopes considering the tumor, the patient's MHC/HLA, his skewed immune responses, etc.
Comments
I was recently in a similar situation, not concerning glioblastoma but a different type of solid tumor. I'd look into either neoantigen vaccine trials from reputable universities/companies (e.g. BioNTech) or T cell therapies (e.g. Immunocore). Adding some checkpoint inhibitor as a coadjuvant might help too.
I work in the field and IMHO neoantigen vaccines are the way to go, but personalization of antigen payload is still lacking. This is a bit paradoxical as production is not that expensive, you can get a custom made one for < $6000. The trouble is to pick the right epitopes considering the tumor, the patient's MHC/HLA, his skewed immune responses, etc.